1. GreenA, SwerdlowAJ (1989) Epidemiology of melanocytic nevi. Epidemiol Rev 11: 204–221.
2. McGregorB, PfitznerJ, ZhuG, GraceM, EldridgeA, et al. (1999) Genetic and environmental contributions to size, color, shape, and other characteristics of melanocytic naevi in a sample of adolescent twins. Genet Epidemiol 16: 40–53.
3. WachsmuthRC, GautRM, BarrettJH, SaundersCL, Randerson-MoorJA, et al. (2001) Heritability and gene-environment interactions for melanocytic nevus density examined in a U.K. adolescent twin study. J Invest Dermatol 117: 348–352.
4. WachsmuthRC, TurnerF, BarrettJH, GautR, Randerson-MoorJA, et al. (2005) The effect of sun exposure in determining nevus density in UK adolescent twins. J Invest Dermatol 124: 56–62.
5. FalchiM, BatailleV, HaywardNK, DuffyDL, BishopJA, et al. (2009) Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet 41: 915–919.
6. ZhuG, MontgomeryGW, JamesMR, TrentJM, HaywardNK, et al. (2007) A genome-wide scan for naevus count: linkage to CDKN2A and to other chromosome regions. Eur J Hum Genet 15: 94–102.
7. AutierP, BoniolM, SeveriG, GilesG, CattaruzzaMS, et al. (2001) The body site distribution of melanocytic naevi in 6-7 year old European children. Melanoma Res 11: 123–131.
8. DoddAT, MorelliJ, MokrohiskyST, AsdigianN, ByersTE, et al. (2007) Melanocytic nevi and sun exposure in a cohort of Colorado children: anatomic distribution and site-specific sunburn. Cancer Epidemiol Biomarkers Prev 16: 2136–2143.
9. HarrisonSL, BuettnerPG, MacLennanR (1999) Body-site distribution of melanocytic nevi in young Australian children. Arch Dermatol 135: 47–52.
10. WhitemanDC, BrownRM, PurdieDM, HughesMC (2005) Melanocytic nevi in very young children: the role of phenotype, sun exposure, and sun protection. J Am Acad Dermatol 52: 40–47.
11. DennisLK, WhiteE, LeeJA, KristalA, McKnightB, et al. (1996) Constitutional factors and sun exposure in relation to nevi: a population-based cross-sectional study. Am J Epidemiol 143: 248–256.
12. KellyJW, RiversJK, MacLennanR, HarrisonS, LewisAE, et al. (1994) Sunlight: a major factor associated with the development of melanocytic nevi in Australian schoolchildren. J Am Acad Dermatol 30: 40–48.
13. ValiukevicieneS, MisevicieneI, GollnickH (2005) The prevalence of common acquired melanocytic nevi and the relationship with skin type characteristics and sun exposure among children in Lithuania. Arch Dermatol 141: 579–586.
14. DennisLK, WhiteE, McKnightB, KristalA, LeeJA, et al. (1996) Nevi and migration within the United States and Canada: a population-based cross-sectional study. Cancer Causes Control 7: 464–473.
15. FritschiL, McHenryP, GreenA, MackieR, GreenL, et al. (1994) Naevi in schoolchildren in Scotland and Australia. Br J Dermatol 130: 599–603.
16. NguyenTD, SiskindV, GreenL, FrostC, GreenA (1997) Ultraviolet radiation, melanocytic naevi and their dose-response relationship. Br J Dermatol 137: 91–95.
17. RichardMA, GrobJJ, GouvernetJ, CulatJ, NormandP, et al. (1994) [Role of sun exposure on benign melanocytic nevi. A first study in populations controlled for age, sex and phenotype.]. Ann Dermatol Venereol 121: 639–644.
18. RodvallY, WahlgrenCF, UllenH, WiklundK (2007) Common melanocytic nevi in 7-year-old schoolchildren residing at different latitudes in Sweden. Cancer Epidemiol Biomarkers Prev 16: 122–127.
19. DriscollMS, Grant-KelsJM (2007) Hormones, nevi, and melanoma: an approach to the patient. J Am Acad Dermatol 57: 919–931.
20. RubegniP, SbanoP, BurroniM, CeveniniG, BocchiC, et al. (2007) Melanocytic skin lesions and pregnancy: digital dermoscopy analysis. Skin Res Technol 13: 143–147.
21. SlominskiA, TobinDJ, ShibaharaS, WortsmanJ (2004) Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev 84: 1155–1228.
22. GandiniS, SeraF, CattaruzzaMS, PasquiniP, AbeniD, et al. (2005) Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41: 28–44.
23. MellemkjaerL, ChristensenJ, FrederiksenK, PukkalaE, WeiderpassE, et al. (2011) Risk of primary non-breast cancer after female breast cancer by age at diagnosis. Cancer Epidemiol Biomarkers Prev 20: 1784–1792.
24. YangGB, Barnholtz-SloanJS, ChenY, BordeauxJS (2011) Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer. Arch Dermatol 147: 1395–1402.
25. MitchellPJ, Perez-NadalesE, MalcolmDS, LloydAC (2003) Dissecting the contribution of p16(INK4A) and the Rb family to the Ras transformed phenotype. Mol Cell Biol 23: 2530–2542.
26. KvaskoffM, MesrineS, Clavel-ChapelonF, Boutron-RuaultMC (2009) Endometriosis risk in relation to naevi, freckles and skin sensitivity to sun exposure: the French E3N cohort. Int J Epidemiol 38: 1143–1153.
27. KvaskoffM, BijonA, MesrineS, Clavel-ChapelonF, Boutron-RuaultMC (2010) Pigmentary traits and risk of endometriosis. Hum Reprod 25: 3157–3158.
28. RedondoP, IdoateM, De FelipeI (1998) Nevi related to thyroid diseases. Arch Intern Med 158: 1577.
29. Clavel-ChapelonF, van LiereMJ, GiuboutC, NiravongMY, GoulardH, et al. (1997) E3N, a French cohort study on cancer risk factors. E3N Group. Etude Epidemiologique aupres de femmes de l'Education Nationale. Eur J Cancer Prev 6: 473–478.
30. VerdeboutJ (2004) A European satellite-derived UV climatology available for impact studies. Radiat Prot Dosimetry 111: 407–411.
31. ResnikS (1967) Melasma induced by oral contraceptive drugs. JAMA 199: 601–605.
32. BorgesV, PuigS, MalvehyJ (2011) [Melanocytic nevi, melanoma, and pregnancy.]. Actas Dermosifiliogr 102: 650–657.
33. BradfordPT, FreedmanDM, GoldsteinAM, TuckerMA (2010) Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 146: 265–272.
34. GogginsW, GaoW, TsaoH (2004) Association between female breast cancer and cutaneous melanoma. Int J Cancer 111: 792–794.
35. SoerjomataramI, LouwmanWJ, LemmensVE, CoeberghJW, de VriesE (2008) Are patients with skin cancer at lower risk of developing colorectal or breast cancer? Am J Epidemiol 167: 1421–1429.
36. SpanogleJP, ClarkeCA, AronerS, SwetterSM (2010) Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study. J Am Acad Dermatol 62: 757–767.
37. WassbergC, ThornM, YuenJ, HakulinenT, RingborgU (1999) Cancer risk in patients with earlier diagnosis of cutaneous melanoma in situ. Int J Cancer 83: 314–317.
38. EwertzM, MouridsenHT (1985) Second cancer following cancer of the female breast in Denmark, 1943–80. Natl Cancer Inst Monogr 68: 325–329.
39. GalperS, GelmanR, RechtA, SilverB, KohliA, et al. (2002) Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys 52: 406–414.
40. HarveyEB, BrintonLA (1985) Second cancer following cancer of the breast in Connecticut, 1935–82. Natl Cancer Inst Monogr 68: 99–112.
41. KirovaYM, De RyckeY, GambottiL, PiergaJY, AsselainB, et al. (2008) Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer 98: 870–874.
42. MellemkjaerL, FriisS, OlsenJH, SceloG, HemminkiK, et al. (2006) Risk of second cancer among women with breast cancer. Int J Cancer 118: 2285–2292.
43. ProchazkaM, HallP, GranathF, CzeneK (2006) Family history of breast cancer and young age at diagnosis of breast cancer increase risk of second primary malignancies in women: a population-based cohort study. Br J Cancer 95: 1291–1295.
44. RubinoC, de VathaireF, DialloI, ShamsaldinA, LeMG (2000) Increased risk of second cancers following breast cancer: role of the initial treatment. Breast Cancer Res Treat 61: 183–195.
45. SchaapveldM, VisserO, LouwmanMJ, de VriesEG, WillemsePH, et al. (2008) Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. J Clin Oncol 26: 1239–1246.
46. SoerjomataramI, LouwmanWJ, de VriesE, LemmensVE, KlokmanWJ, et al. (2005) Primary malignancy after primary female breast cancer in the south of the Netherlands, 1972–2001. Breast Cancer Res Treat 93: 91–95.
47. VolkN, Pompe-KirnV (1997) Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control 8: 764–770.
48. YuGP, SchantzSP, NeugutAI, ZhangZF (2006) Incidences and trends of second cancers in female breast cancer patients: a fixed inception cohort-based analysis (United States). Cancer Causes Control 17: 411–420.
49. BorgA, SandbergT, NilssonK, JohannssonO, KlinkerM, et al. (2000) High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 92: 1260–1266.
50. de SnooFA, HaywardNK (2005) Cutaneous melanoma susceptibility and progression genes. Cancer Lett 230: 153–186.
51. BishopDT, DemenaisF, IlesMM, HarlandM, TaylorJC, et al. (2009) Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 41: 920–925.
52. TurnbullC, AhmedS, MorrisonJ, PernetD, RenwickA, et al. (2010) Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42: 504–507.
53. NickelsS, TruongT, HeinR, StevensK, BuckK, et al. (2013) Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet 9: e1003284.
54. Agarwal P, Lutful Kabir FM, DeInnocentes P, Bird RC (2012) Tumor suppressor gene p16/INK4A/CDKN2A and its role in cell cycle exit, differentiation, and determination of cell fate. In: Cheng Y, editor. Tumor suppressor genes. Rijeka (Croatia): InTech.
55. Doisneau-SixouSF, SergioCM, CarrollJS, HuiR, MusgroveEA, et al. (2003) Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 10: 179–186.
56. LiuT, NiuY, FengY, NiuR, YuY, et al. (2008) Methylation of CpG islands of p16(INK4a) and cyclinD1 overexpression associated with progression of intraductal proliferative lesions of the breast. Hum Pathol 39: 1637–1646.
57. DebniakT, GorskiB, HuzarskiT, ByrskiT, CybulskiC, et al. (2005) A common variant of CDKN2A (p16) predisposes to breast cancer. J Med Genet 42: 763–765.
58. BaxterAJ, HughesMC, KvaskoffM, SiskindV, ShekarS, et al. (2008) The Queensland Study of Melanoma: environmental and genetic associations (Q-MEGA); study design, baseline characteristics, and repeatability of phenotype and sun exposure measures. Twin Res Hum Genet 11: 183–196.
59. GlanzK, SchoenfeldE, WeinstockMA, LayiG, KiddJ, et al. (2003) Development and reliability of a brief skin cancer risk assessment tool. Cancer Detect Prev 27: 311–315.
60. WesterdahlJ, AndersonH, OlssonH, IngvarC (1996) Reproducibility of a self-administered questionnaire for assessment of melanoma risk. Int J Epidemiol 25: 245–251.
61. Clavel-ChapelonF, Dormoy-MortierN (1998) A validation study on status and age of natural menopause reported in the E3N cohort. Maturitas 29: 99–103.
62. RacineA, BijonA, FournierA, MesrineS, Clavel-ChapelonF, et al. (2013) Menopausal hormone therapy and risk of cholecystectomy: a prospective study based on the French E3N cohort. CMAJ 185: 555–561.
63. TehardB, van LiereMJ, Com NougueC, Clavel-ChapelonF (2002) Anthropometric measurements and body silhouette of women: validity and perception. J Am Diet Assoc 102: 1779–1784.
64. KvaskoffM, MesrineS, FournierA, Boutron-RuaultMC, Clavel-ChapelonF (2007) Personal history of endometriosis and risk of cutaneous melanoma in a large prospective cohort of French women. Arch Intern Med 167: 2061–2065.
65. RothmanKJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1: 43–46.
66. EngelP, FagherazziG, BouttenA, DupreT, MesrineS, et al. (2010) Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 19: 2341–2350.